Trials / Completed
CompletedNCT00320398
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fondaparinux |
Timeline
- Start date
- 2006-01-30
- Primary completion
- 2006-07-18
- Completion
- 2006-07-18
- First posted
- 2006-05-03
- Last updated
- 2018-09-04
- Results posted
- 2017-12-21
Source: ClinicalTrials.gov record NCT00320398. Inclusion in this directory is not an endorsement.